Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
Mosunetuzumab-axgb 30 MG/30ML Soln 30 mL Vial (NDC 50242-0142-01) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved November 21, 2026 , from http://ppman.hank.ai/transparency/procedure/50242-0142-01/by-state?code_type=NDC
“Mosunetuzumab-axgb 30 MG/30ML Soln 30 mL Vial (NDC 50242-0142-01) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/50242-0142-01/by-state?code_type=NDC. Accessed
November 21, 2026 .
“Mosunetuzumab-axgb 30 MG/30ML Soln 30 mL Vial (NDC 50242-0142-01) by State,” HANK Price Transparency ,
accessed November 21, 2026 ,
http://ppman.hank.ai/transparency/procedure/50242-0142-01/by-state?code_type=NDC.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
NDC · across United States
50242-0142-01 — Mosunetuzumab-axgb 30 Mg/30ml Soln 30 Ml Vial
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$100,661
National median
$85,436 – $140,926
IQR (p25 – p75)
2
hospitals filing
1
states
Walking in without insurance?
Cash / self-pay price
Cash median
$124,820
vs. negotiated
+24.0%
Hospitals reporting
8
Cash / self-pay rates apply when you don't run the bill through insurance.
Many hospitals also offer income-based discounts on top of the published
cash price — always ask about a financial-assistance application
before paying.
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for 50242-0142-01 (NDC), with interquartile range
State Median p25 p75
PA $100,661 $85,436 $140,926